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Abstract
We performed association studies with 5,151 SNPs that were judged as likely candidate genetic
variations conferring susceptibility to anorexia nervosa (AN) based on location under reported
linkage peaks, previous results in the literature (182 candidate genes), brain expression, biological
plausibility, and estrogen responsivity. We employed a case–control design that tested each SNP
individually as well as haplotypes derived from these SNPs in 1,085 case individuals with AN
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diagnoses and 677 control individuals. We also performed separate association analyses using three
increasingly restrictive case definitions for AN: all individuals with any subtype of AN (All AN: n
= 1,085); individuals with AN with no binge eating behavior (AN with No Binge Eating: n = 687);
and individuals with the restricting subtype of AN (Restricting AN: n = 421). After accounting for
multiple comparisons, there were no statistically significant associations for any individual SNP or
haplotype block with any definition of illness. These results underscore the importance of large
samples to yield appropriate power to detect genotypic differences in individuals with AN and also
motivate complementary approaches involving Genome-Wide Association (GWA) studies, Copy
Number Variation (CNV) analyses, sequencing-based rare variant discovery assays, and pathway-
based analysis in order to make up for deficiencies in traditional candidate gene approaches to AN.
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single nucleotide polymorphisms; probands; anorexia nervosa; bulimia nervosa
INTRODUCTION
Anorexia nervosa (AN) is a potentially chronic illness with extremely high morbidity and
mortality for which no generally agreed upon model of etiology presently exists [Sullivan,
1995; Birmingham et al., 2005]. In spite of the chronicity and high economic burden it confers,
the effects of currently applied treatment approaches remain largely disappointing. Although
psychosocial factors were long implicated in its etiology [Striegel-Moore and Bulik, 2007], a
growing body of evidence now supports the role of genetic influences, although no specific
variants have been definitively implicated as causal to date [Bulik et al., 2007]. In this light,
however, the familiality of AN has now been well established, with first-degree female relatives
of individuals with AN having an approximately 10-fold greater lifetime risk of having an
eating disorder compared with relatives of unaffected individuals [Lilenfeld et al., 1998;
Strober et al., 2000]. Heritability estimates for AN have ranged from 46% to 78% [Wade et
al., 2000; Klump et al., 2001; Kortegaard et al., 2001; Bulik et al., 2006]. The convergent
findings from family and twin studies have motivated efforts to identify loci that contribute to
risk for AN through linkage and association studies.
A previous study from our group that applied linkage analysis to affected relatives with the
restricting type of AN yielded significant evidence for a susceptibility locus in the 1p33–36
region [Grice et al., 2002]. In addition, enhancements to traditional linkage analyses that have
incorporated key behavioral covariates such as drive for thinness and obsessionality have
resulted in suggestive linkages on chromosomes 1, 2, and 13 [Devlin et al., 2002].
Specific candidate gene approaches have targeted neurotransmitter and neuropeptide systems,
and have included a variety of serotonergic, epinephrine/norepinephrine and dopaminergic
genes, genes coding for proteins associated with the melanocortin system, and genes for leptin,
ghrelin, agouti-related protein, neuropeptide Y, opioids, cannabinoid receptors, potassium
channels, brain derived neurotrophic factor, and reproductive hormones. Several reviews have
been published detailing the results of these studies [Tozzi et al., 2002; Hinney et al., 2004;
Klump and Gobrogge, 2005; Slof-Op ’t Landt et al., 2005; Bulik et al., 2007]. Overall,
association studies have yielded sporadically significant and typically non-replicated findings
[Bulik et al., 2007] highlighting the methodological and statistical challenges associated with
genetic studies of a relatively low prevalence disorder (e.g., small sample sizes, lack of power,
multiple testing issues, and varying phenotypic definitions) [Balding, 2006]. As with other,
and perhaps all, complex traits, it is likely that susceptibility to disease is comprised of multiple,
relatively common genetic variants each of which confers only small to modest risk in
conjunction with environmental factors, a model of disease that will require approaches that
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increase the number of target genes and single nucleotide polymorphisms (SNPs) investigated.
Nonetheless, in the literature on AN, some associations have been replicated, with the
accumulated data suggesting the involvement of HTR1D and OPRD1 [Bergen et al., 2003;
Brown et al., 2006], SLC6A4 [Gorwood, 2004], and BDNF [Ribases et al., 2004; Gratacos et
al., 2008].
Accordingly, we present herein the results of a case–control association study in a sample of
1,085 unrelated women with a lifetime history of AN and 677 unrelated controls ascertained
in the multisite Price Foundation Genetic Studies of Eating Disorders initiative between 1996
and 2002 [Kaye et al., 2000, 2004; Reba et al., 2005]. We tested 5,151 SNPs as well as the
derived haplotypes from these SNPs for association to three progressively more restrictive
phenotypic definitions of anorexia nervosa. We selected a total of 182 candidate genes that
had been previously identified in case–control candidate gene association analyses, genes
under linkage peaks for anorexia nervosa and bulimia nervosa [Devlin et al., 2002; Grice et
al., 2002; Bulik et al., 2003; Bacanu et al., 2005], genes with evidence of expression in the
brain, biologically plausible genes, and genes that were known to be estrogen responsive from
microarray studies.
MATERIALS AND METHODS
Participants
Participants of primarily European decent were from the three multisite international Price
Foundation Genetic Studies of Eating Disorders: the Anorexia Nervosa Affected Relative Pair
Study, the Bulimia Nervosa Affected Relative Pair Study, and the Anorexia Nervosa Trios
Study [Kaye et al., 2000, 2004; Reba et al., 2005]. Each study was designed to identify
susceptibility loci involved in risk for eating disorders. Informed consent was obtained from
all study participants, and all sites received approval from their local Institutional Review
Board. Brief descriptions of each study are provided below.
AN affected relative pair study—The sample for this study included both probands and
affected relatives. Probands met the following criteria: (1) lifetime diagnosis of AN by DSM-
IV criteria excluding the amenorrhea criterion because of the unreliability of its retrospective
assessment in females, and replicated data indicating that individuals with and without
amenorrhea do not differ meaningfully [Gendall et al., 2006; Poyastro Pinheiro et al., 2007];
(2) low weight that is/was less than the 5th percentile of body mass index (BMI) for age and
gender according to the Hebebrand et al. [1996] NHANES chart; (3) ages 13 and 65 years; (4)
eating disorder onset prior to age 25; and (5) having met criteria for AN not less than 3 years
prior to ascertainment. Affected relatives were defined as biological family members who were
(1) between the ages of 13 and 65 years, and (2) had lifetime eating disorder diagnoses of
modified DSM-IV AN (again excluding amenorrhea), lifetime eating disorder diagnoses of
DSM-IV bulimia nervosa (BN)-purging type or nonpurging type, or an eating disorder not
otherwise specified (EDNOS)—sub-threshold AN, sub-threshold BN, or sub-threshold mixed
(relatives who were normal weight but reported either purging behavior or excessive exercise
or periods of fasting due to extreme fear of weight gain or undue influence of body weight on
self-esteem). For the complete list of inclusion and exclusion criteria for probands and relatives,
see Kaye et al. [2000].
BN affected relative pair study—The sample for this study included probands and affected
relatives. Probands met the following criteria: (1) DSM-IV diagnosis of BN—purging type,
with the additional requirement of at least a 6-month period of binge eating and vomiting at
least twice a week; and (2) ages 13 to 65. Affected relatives were defined as biological family
members who were (1) between the ages of 13 and 65 years, and (2) had a lifetime eating
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disorder diagnoses of modified DSM-IV AN (i.e., amenorrhea not required), DSM-IV BN—
purging type or non-purging type, or eating disorder not otherwise specified EDNOS as defined
above. For the complete list of inclusion and exclusion criteria for pro-bands and relatives, see
Kaye et al. [2004].
AN Trios study—The sample for this study included individuals with AN and their parents
as well as a sample of control women. Probands were required to meet the following criteria:
(1) modified DSM-IV lifetime diagnosis of AN, with or without amenorrhea; (2) low weight
that is/was less than 5th percentile of BMI for age and gender according to the Hebebrand et
al. [1996] NHANES chart; (3) onset prior to age 25; (4) weight that is/was controlled through
restricting and/or purging; (5) between the ages of 13 and 65; and (6) study diagnostic criteria
were met at least 3 years prior to entry into the study. Potential affected participants were
excluded if they reported maximum BMI since puberty >27 kg/m2 for females and >27.8 kg/
m2 for males to limit any potential genetic signals from obesity. Parents were encouraged to
participate regardless of age, weight, or psychiatric diagnosis.
In the AN Trios Study, healthy control women were recruited to serve as a comparison group
for the affected individuals. These women were recruited by advertisements in the local
communities of the participating sites. Participants in the control group were (1) between the
ages of 18 and 65 years, (2) at normal weight with a lifetime adult BMI 19–27 kg/m2, and (3)
matched with the eating disorder participants based on site, age range, ancestry, and highest
educational level completed. BMI exclusions were designed to screen for eating disorders (on
the low end) and obesity on the upper end to be consistent with exclusion criteria in the eating
disorders groups. Participants in the control group were excluded if they: (1) reported history
of an eating disorder or eating disordered behaviors, as defined by a score of 20 or higher on
the Eating Attitudes Test [Garner et al., 1982]; (2) had a first degree relative with an eating
disorder; or (3) had any of the following as defined by the presence of an Axis I disorder on
the Structured Clinical Interview for DSM-IV (SCID) Screen Patient Questionnaire [First et
al., 1997]: mood disorders, anxiety disorders, alcohol dependence and abuse, other substance
dependence and abuse, somatoform disorders, eating disorders, and schizophrenia and other
psychotic disorders. Participants in the control group completed the same battery of self-report
assessments as probands, which covered personality and symptom measures.
Participant Selection for Association Studies
From the three studies above, a total of 2,257 individuals were selected for these association
studies. Participants were first chosen based on whether an adequate genomic DNA sample
was available. Then, participants were ordered using a diagnostic hierarchy (highest to lowest),
regardless of whether they were probands or affected relatives: restricting AN (RAN), AN with
purging but no binging (PAN), AN with binge eating with or without purging (BAN), a lifetime
history of both AN and BN (ANBN), subthreshold AN with no binging or purging, purging
BN, non-purging BN, and subthreshold BN. The individual from each family with the diagnosis
that was highest on the hierarchy was selected. These participants as well as 677 control women
from the AN Trios Study were defined as the primary samples for inclusion. A secondary set
of samples was selected based on the criteria above and each of these participants was related
to one individual in the primary sample. Genomic DNA samples from these individuals were
sent to Illumina for genotyping. Of these individuals, we removed 11 participants whose DNA
samples failed genotyping; 220 participants who were included for quality control purposes;
and 264 participants included to support pilot projects (27 males with AN, 121 first-degree
relatives, and 116 individuals with eating disorder diagnoses other than AN). No participants
were excluded due to excessive genotype missingness (all were ≤0.021). Thus the overall
sample includes 1,762 female participants (1,085 cases and 677 controls). In this analysis
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sample, there were 10 families with two second-degree relatives, 15 families with two third-
degree relatives, and three families with two fourth-degree relatives.
Table I presents the abbreviations and definitions of illness on which we based our samples
for analysis. We chose three increasingly restrictive definitions of AN based on the literature
and previous linkage analysis results [Devlin et al., 2002;Grice et al., 2002]. For all definitions,
participants were required to meet all DSM-IV criteria for AN except Criterion D, amenorrhea.
The first analysis was conducted on the sample defined by the broadest definition of illness
(All AN; N = 1,085). This sample included 415 individuals with RAN, 266 with PAN, 132
with BAN, 266 with ANBN, and 6 with subthreshold AN with no binging or purging. The
second analysis was based on a sample defined as AN with No Binge Eating (N = 687) and
included only individuals with AN subtypes that did not include regular binge eating. This
definition of illness was chosen due to the fact that the presence of binge eating has been
identified as a distinguishing feature within the AN diagnostic category [Herzog et al., 1996].
This sample comprised 415 individuals with RAN, 266 with PAN, and 6 with subthreshold
AN with no binging or purging. The third analysis included the narrowest definition of illness,
namely Restricting AN (N = 421), based on previous linkage analyses that identified significant
and suggestive linkage signals based on a case definition of Restricting AN [Devlin et al.,
2002;Grice et al., 2002]. This sample included 415 individuals with RAN and 6 individuals
with subthreshold AN with no binging or purging. The AN with No Binge Eating sample was
a subset of the All AN sample, and the Restricting AN sample was a subset of the AN with No
Binge Eating sample.
Candidate Gene and SNP Selection
Candidate genes were selected by the investigators via a consensus process. First, genes
residing under reported eating disorders linkage peaks were identified using SLEP [Konneker
et al., 2008]. Second, an exhaustive search of the literature was conducted to identify plausible
candidate genes based on previous findings reported in the eating disorders literature, published
findings in other related disorders, and genes involved in pathways thought to be implicated
in AN. This inclusive list was limited by selecting genes with evidence of expression in the
brain and by genes that were shown to be estrogen responsive in microarray studies. Based on
the RefSeq data base [Pruitt et al., 2007] accessed in 3/2007, these combined approaches
yielded a list of 247 genes which were then necessarily prioritized by consensus to match
available genotyping budget and winnowed to 190 plausible candidate genes. See supplemental
material for the complete gene list.
SNP selection was conducted in two rounds. These 190 candidate genes were processed by
TAMAL v2.0 [Hemminger et al., 2006], indicating that 186 could be uniquely mapped. SNPs
were selected to tag common variation in Europeans (using TAGGER, aggressive tagging,
r2 threshold 0.8, and any coding SNPs forced in). Additional SNPs with MAF ≥0.05 in splice
sites, exons (synonymous or non-synonymous), and highly conserved regions were selected
along with SNPs in predicted promoter, regulatory, transcription factor binding, and micro
RNA target sites. The final list comprised 186 genes and 6,568 SNPs and was sent to Illumina
for genotyping with their Custom Infinium Genotyping Beadchips platform.
SNP Quality Control
Despite favorable design scores, the SNP assay design process failed at Illumina for 480 SNPs.
An additional 237 SNPs failed genotyping and genotypes for 5,851 SNPs were delivered.
Quality control (QC) filters were then applied and a total of 700 SNPs failed for the following
reasons (note that a SNP could fail for more than one reason): minor allele frequency (MAF)
<0.01 (538 SNPs); AN Trios (affected individual with two parents, parents only used for QC)
with ≥2 Mendel errors (1 SNP); duplicate samples with ≥2 disagreements (111 SNPs); missing
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genotypes in >0.05 of cases or controls (24 SNPs); differential genotype missingness in cases
versus controls at P <0.01 (4 SNPs); and Hardy–Weinberg equilibrium (HWE) exact P <0.01
in controls (47 SNPs). The total number of SNPs passing all QC steps was 5,151. The total
number of genes with SNPs passing all QC steps was 182. In addition, the plot of homozygosity
over all SNPs showed no significant differences between cases and controls (P = 0.35) and no
individual had marked elevated homozygosity. Finally, population stratification was assessed
through genomic control [Devlin and Roeder, 1999]: lambda (λ) = 1.035 is consistent with an
acceptably small amount of population stratification.
Statistical Analyses
PLINK [Purcell et al., 2007] was used to conduct all association analyses. The principal test
for association was the 1 degree-of-freedom Cochran-Armitage trend test. For each analysis,
multiple testing correction was accomplished using the false discovery rate approach
[Benjamini and Hochberg, 1995; Benjamini et al., 2001]. Haplotype analyses using tagging
SNPs were also performed. Haplotype blocks for these 5,151 SNPs were defined using the
TAGGER method in Haploview 4.0 [Barrett et al., 2005]. The Haploview algorithm creates
blocks if 95% of informative comparisons are in strong linkage disequilibrium. These blocks,
ranging in size from 2 SNPs to 79 SNPs (chr 14), were then imported into PLINK for haplotype
analysis. Because linkage disequilibrium was used to generate haplotype blocks, the sliding
window method for haplotype analysis was not applied. Quanto [Gauderman, 2002] was used
to approximate statistical power (0.80) given the following assumptions: two-tailed P = 9.7 ×
10−6 (Bonferroni correction for 5,151 SNPs), lifetime morbid risk of AN of 0.009 [Hudson et
al., 2007], and a log additive genetic model. For the broad phenotype, All AN, (1,085 AN cases,
677 controls), the minimum detectible genotypic relative risks were 1.8, 1.5, and 1.5 for minor
allele frequencies of 0.10, 0.25, and 0.40. For the AN with No Binge Eating phenotype, (687
cases, 677 controls), the minimum detectible genotypic relative risks were 1.9, 1.6, and 1.5 for
minor allele frequencies of 0.10, 0.25, and 0.40. For the narrow phenotype, Restricting AN,
(421 cases, 677 controls), the minimum detectible genotypic relative risks are 2.0, 1.7, and 1.6
for minor allele frequencies of 0.10, 0.25, and 0.40.
RESULTS
Results for the All AN Phenotype
Table II presents the 25 most significant SNPs from the association analyses conducted on the
broadest definition of illness, that is, the All AN phenotype. The λ for All AN was 1.01, close
to unity, which is consistent with a lack of stratification artifacts. The minimum p value using
the trend test was 4.7 × 10−5, which corresponds to an FDR of 0.22, suggesting no significant
differences between cases and controls. Table II also presents the p values and FDR for those
top 25 SNPs from the analyses reported below for the AN with No Binge Eating and Restricting
AN phenotypes for comparison. Figure 1a presents the QQ plot for this comparison. The QQ
plot is based on P-values that correspond to the 1 degree-of-freedom Wald test on 5,151
autosomal SNPs by assuming an additive risk model. The observed values correspond closely
to that expected by chance.
Results for the AN With No Binge Eating Phenotype
Table III presents the top 25 SNPs for analyses conducted on the AN with No Binge Eating
sample. The λ for AN with No Binge Eating was 1.005, also close to unity, which is not
consistent with the presence of stratification artifacts. Using the trend test, the minimum P-
value was 1.9 × 10−4, corresponding to an FDR of 0.62, suggesting no statistically significant
differences between cases and controls. Figure 1b shows the QQ plot and again shows no
deviation of observed from expected P-values.
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Results for the Restricting AN Phenotype
Table IV presents the top 25 SNPs for analyses conducted on the Restricting AN sample. The
λ for Restricting AN was 1.0. The minimum P-value using the trend test was 4.7 × 10−4, which
corresponds to an FDR of 0.91. Figure 1c depicts the QQ plot with no deviation of observed
from expected P-values. Again, the observed P-value distribution corresponds closely to that
expected by chance.
Haplotype Analyses
No haplotypes reached the statistical threshold of 5 × 10−7. Results for the top 25 haplotypes
for analyses conducted on each of the samples are available in the supplementary material.
DISCUSSION
Discovering genetic variants that confer risk to AN has the potential to illuminate pathways
relevant to both etiopathogenesis and drug development efforts. However, to date replicable
associations of candidate gene tagging and coding SNPs with diagnostic categories have mostly
eluded the eating disorders field. The present study arguably represents the most
comprehensive candidate-gene-based approach conducted in eating disorders. We performed
association tests with SNPs and haplotypes to detect associations with a priori defined statistical
thresholds to three eating disorder case–control datasets, where the cases were nested based
on binging and purging. We studied a relatively large sample, selected high probability
candidate genes, used tagging and coding SNPs, and applied conservative quality control and
multiple test correction procedures. However, these association analyses yielded no
statistically significant results.
The current study’s failure to identify significant associations does not mean that associations
do not exist. Although statistically nonsignificant, our top SNP is noteworthy in that the
GLP2R, which is a member of the G protein-coupled receptor superfamily, is a receptor for a
33-amino acid proglucagon-derived peptide (GLP2), both expressed primarily in the gut. GLP2
has been shown to slow the ingestion and transit of food through the GI tract [Burrin et al.,
2001]. While there is no evidence to suggest that systemic administration of GLP2 is associated
with food intake, central administration of GLP2 in the lateral cerebral ventricle has been shown
to inhibit food intake in rats [Tang-Christensen et al., 1996; Drucker, 1998]. GLP2 is also
related to homeostatic control of human body weight in that GLP2 acts as a neurotransmitter
linking the brainstem with the dorsal medial hypothalamic nucleus [Tang-Christensen et al.,
2000]. Our second top SNP is associated with the PAH gene which codes for the enzyme
phenylalanine hydroxylase [Scriver, 2007]. Phenylalanine hydroxylase is responsible for the
conversion of phenylalanine to tyrosine. Phenylalanine is found in all proteins and some
artificial sweeteners. Mutations in the PAH gene are most commonly associated with
phenylketonuria (PKU), an inherited disorder which increases levels of phenylalanine in the
blood [Erlandsen et al., 2003].
Finally, the top two SNPS located on chromosome 1 are also worth mentioning given that
significant over-representation of KCNN3 alleles with longer CAG repeats have been
previously reported in AN patients [Koronyo-Hamaoui et al., 2002, 2004]. The small-
conductance calcium-activated potassium channel gene KCNN3 is expressed in brain;
increased expression in the hippocampus has been associated with reduced long-term
potentiation [Blank et al., 2003]. Although several studies have reported positive associations
of increased CAG-repeat length of KCNN3 with schizophrenia and bipolar disorder, a recent
meta-analysis casts doubt on this association, while leaving open the possibility that other
aspects of this polymorphism may contribute to specific features of these disorders [Glatt et
al., 2003].
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This study had significant strengths including a five-nation cooperative and coordinated case
and control ascertainment consortium, comprehensive phenotyping that was carefully designed
and coordinated, and gene selection procedures designed to optimize findings. Nonetheless,
the study was underpowered, limiting our ability to detect significant effects. After FDR
corrections, the smallest P-value observed was 0.2125 for SNP rs4791362 on gene GLP2R for
the All AN analyses. This corresponds to a relative risk of 1.3, 1.2, and 1.2 for minor allele
frequencies of 0.10, 0.25, and 0.40. Using statistical power of 0.80, in a 1:1 unmatched case/
control study, the minimum sample sizes needed to obtain significance for these relative risks
are approximately 4,050, 4,270, and 3,430, respectively, three to four times the number of the
participants in this study. Lack of power is a common problem faced by consortia studying the
genetics of relatively rare phenotypes such as AN. Statistical power was particularly weakened
as case numbers dropped with the increasingly restrictive definitions of AN. Our approach to
case definition was based on previous findings (i.e., stronger linkage signals with more
restrictive case definitions). However, there are two concerns with narrowing the case
definition: (1) statistical power is reduced, and (2) other case definition restrictions may lead
to different results. In addition, although our strategy of selecting high-probability candidate
genes was scientifically defensible, it is noteworthy that many genetic variants identified by
genomewide association studies have not emerged from lists of “usual suspects” and have been
genes previously not thought to be involved in the target disease etiology [Psychiatric GWAS
Consortium (PGC), 2009].
Our results, in conjunction with the published inconsistent findings in single candidate-gene
studies, underscore the critical need for larger samples but also additional analytic approaches
to detect genotypic differences between individuals with and without AN. In this context, as
we better appreciate the nature of diverse individual differences in trait characteristics,
cognitions and affective processes, and symptomatic behaviors with broadly defined
diagnostics classes, it will be essential for genetic analyses of AN to make better use of
empirically derived phenotype selection criteria that integrate neural systems information with
these behavioral data.
Following these points, several complementary approaches exist. One alternative is a
genomewide association (GWA) scan on AN. GWA studies have been successful in identifying
highly replicable associations for T1DM, T2DM, Crohn’s disease, cardiovascular disease,
prostate cancer, breast cancer, body mass index, nicotine addiction, and height [Bierut et al.,
2007; Consortium, 2007; Frayling et al., 2007; Saxena et al., 2007; Scott et al., 2007; Berrettini
et al., 2008; Thorgeirsson et al., 2008]. Whether similar successes will be realized in psychiatry
remains unclear although many efforts are currently underway [Psychiatric GWAS Consortium
(PGC), 2009]. Critical to note is that our approach focused on common variants (MAF >0.5%),
and thus rare variation has been necessarily missed. Our results do not eliminate these genes
as potential candidates for AN, but rather indicate that common variants located in them are
unlikely to be the causal variants. Other approaches include searches for multiple rare variations
via sequencing studies [Nejentsev et al., 2009], analysis of copy number variations [Walsh et
al., 2008], accommodation and consideration of epigenomic factors [Peedicayil, 2004] and
sophisticated multi-locus analyses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIG. 1.
QQ plots for All AN (a), AN with No Binge Eating (b), and Restricting AN (c). The dashed
lines show the expected 95% probability interval for ordered P values.
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